

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/699,438	10/31/2003	Young Hee Mun	29936/39510	3273
4743 7	590 05/05/2006		EXAM	INER
	, GERSTEIN & BOF	GUERRERO, MARIA F		
	233 S. WACKER DRIVE, SUITE 6300 SEARS TOWER		ART UNIT	PAPER NUMBER
CHICAGO, II	CHICAGO, IL 60606			
			DATE MAILED: 05/05/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Ė				
	Application No.	Applicant(s)				
	10/699,438	MUN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Maria Guerrero	2822				
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirwill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. ED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 16 M	larch 2006.					
3) Since this application is in condition for allowar	☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.				
Disposition of Claims						
4) ☐ Claim(s) 1.3-8.10-13.47 and 48 is/are pending 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1.3-8.10-13.47 and 48 is/are rejected 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/o	wn from consideration.					
Application Papers						
<u> </u>	_	·				
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list 	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate Patent Application (PTO-152)				

Application/Control Number: 10/699,438 Page 2

Art Unit: 2822

DETAILED ACTION

1. This Office Action is in response to the Request for a continued examination filed March 16, 2006.

Status of Claims

2. Claim 2, 9, and 14-46 are canceled. Claims 1, 3-8, 10-13 and 47-48 are pending.

Continued Examination Under 37 CFR 1.114

3. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on March 16, 2006 has been entered.

Priority

4. Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

5. Claims 1, 3-8,11-13 and 47-48 are rejected under 35 U.S.C. 102(b) as being anticipated by Falster et al. (US 5,994,761).

Falster et al. shows a silicon wafer having a front surface, a back surface, a central axis, a circumferential edge portion and a region between the front and back surfaces (col. 2, lines 35-40, 55-67). Falster et al. discloses the silicon wafer comprising a first denuded zone formed to a predetermine distance from the front surface, a second denuded zone formed to a predetermine distance from the back surface (Figs. 1-4, col. 3, lines 1-27). Falster et al. teaches a bulk region formed between the first and the second denuded zones (col. 7, lines 57-67).

Furthermore, Falster et al. describes a concentration profile of defects in the bulk region having a distribution that is maintained substantially constant in a direction from the front to the back surface (Figs. 1-4, col. 7, lines 60-67, col. 13, lines 10-22). Falster et al. shows the concentration of defects being maintained constant in a range of about 1x 10⁷ to about 5x10¹⁰ precipitates/cm³ (col. 8, lines 1-7). Falster et al. teaches the distances of the first and the second zones being at least about 5, 20, 30, 40 micrometers (col. 8, lines 8-45). Falster et al. teaches the concentration profile of

Application/Control Number: 10/699,438

Art Unit: 2822

defects having stepwise shape having an axial symmetry at the center between the front and back surfaces of the wafer (Figs. 1-9). Falster et al. discloses the bulk region having vertically rising concentration gradients at boundaries of the first and second denuded zones and a horizontal concentration gradient over the bulk region and the variation being about 10% or less (Figs. 1-9, col. 8, lines 35-50).

Page 4

- 6. In addition, the elements must be arranged as required by the claim, but this is not an ipsissimis verbis test, i.e., identity of terminology is not required. In re Bond, 910 F.2d 831, 15 USPQ2d 1566 (Fed. Cir. 1990). Therefore, the claims are anticipated by Falster et al.
- 7. Claims 1 and 3-4 and are rejected under 35 U.S.C. 102(b) as being anticipated by Nadahara et al. (US 5,502,010).

Nadahara et al. shows a silicon wafer having a front surface, a back surface, a central axis, a circumferential edge portion and a region between the front and back surfaces (Fig. 11A, col. 2, lines 35-40, 55-67). Nadahara et al. discloses the silicon wafer comprising a first denuded zone formed to a predetermine distance from the front surface, a second denuded zone formed to a predetermine distance from the back surface (col. 1, lines 40-67, col. 2, lines 1-35, col. 4, lines 1-13). Nadahara et al. teaches a bulk region formed between the first and the second denuded zones (col. 1, lines 40-67, col. 2, lines 1-35, col. 4, lines 1-13).

8. Furthermore, Nadahara et al. describes a concentration profile of defects (BMD) (between 10⁷defectes/cm³ and 10⁹defects/cm³ in the bulk region having a distribution

Application/Control Number: 10/699,438 Page 5

Art Unit: 2822

that is maintained substantially constant in a direction from the front to the back surface (col. 4, lines 1-13).

Response to Arguments

- 9. Applicant's arguments filed March 16, 2006 have been fully considered but they are not persuasive. Claims 1, 3-8, 11-13 and 47-48 stand rejected because the amendment does not overcome the Rejections. The claims do not require that the first and second concentration distribution of defects being different. Therefore, in a broad interpretation the references read on the claims.
- 10. In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., **radial distribution** of defect concentration) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).
- 11. Applicant argued that Falster shows that the peak value of vacancy concentration exits, and provides a silicon wafer having a vacancy profile in which the peak density of the vacancies is at or near the central plane with the concentration generally decreasing in the direction of the front surface. In the invention, on the other hand, the bulk micro defects including oxygen precipitates and bulk stacking faults are substantially uniform.

Art Unit: 2822

Nevertheless, Falster et al. describes a concentration profile of defects in the bulk region having a distribution that is maintained substantially constant in a direction from the front to the back surface (Figs. 1-4, col. 7, lines 60-67, col. 13, lines 10-22). Falster et al. shows the concentration of defects being maintained constant in a range of about 1x 10⁷ to about 5x10¹⁰ precipitates/cm³ (col. 8, lines 1-7).

Furthermore, "The use of patents as references is not limited to what the patentees describe as their own inventions or to the problems with which they are concerned. They are part of the literature of the art, relevant for all they contain." In re Heck, 699 F.2d 1331, 1332-33, 216 USPQ 1038, 1039 (Fed. Cir. 1983) (quoting In re Lemelson, 397 F.2d 1006, 1009, 158 USPQ 275, 277 (CCPA 1968)). A reference may be relied upon for all that it would have reasonably suggested to one having ordinary skill the art, including nonpreferred embodiments. Merck & Co. v. Biocraft Laboratories, 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989). See also Celeritas Technologies Ltd. v. Rockwell International Corp., 150 F.3d 1354, 1361, 47 USPQ2d 1516, 1522-23 (Fed. Cir.1998).

Furthermore, during patent examination, the pending claims must be "given *>their< broadest reasonable interpretation consistent with the specification." > In re
Hyatt, 211 F.3d 1367, 1372, 54 USPQ2d 1664, 1667 (Fed. Cir. 2000). While the claims of issued patents are interpreted in light of the specification, prosecution history, prior art and other claims, this is not the mode of claim interpretation to be applied during examination. During examination, the claims must be interpreted as broadly as their terms reasonably allow. > In re American Academy of Science Tech Center, F.3d, 2004

WL 1067528 (Fed. Cir. May 13, 2004)(The USPTO uses a different standard for construing claims than that used by district courts; during examination the USPTO must give claims their broadest reasonable interpretation.) < This means that the words of the claim must be given their plain meaning unless applicant has provided a clear definition in the specification. In re Zletz, 893 F.2d 319, 321, 13 USPQ2d 1320, 1322 (Fed. Cir. 1989) >; Chef America, Inc. v. Lamb-Weston, Inc., 358 F.3d 1371, 1372, 69 USPQ2d 1857 (Fed. Cir. 2004). Therefore, the words in the claims have been given their plain meaning.

Regarding the claimed range of variation of about 10% or less, the claimed range is not specific because is an open range. In addition, the Rejection is maintained because Applicant failed to present any evidence of criticality or unexpected results. In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). See MPEP § 716.02 - § 716.02(g) for a discussion of criticality and unexpected results.

Conclusion

12. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Inoue et al. (US 5,502,331) (cited on IDS) and Park (US 6,485,807) (cited on IDS) are presented as evidence to show that a person of ordinary skill in the art would recognize that the defects described by Falster et al. are in fact bulk microdefects (BMD). Falster et al. (US 5,403,406) shows several embodiments related to applicant's disclosure.

Application/Control Number: 10/699,438 Page 8

Art Unit: 2822

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maria Guerrero whose telephone number is 571-272-1837.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Zandra Smith can be reached on 571-272-24299. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

May 1, 2006

MARIA F. GUERRERO PRIMARY EXAMINER